Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisdexamfetamine - Shionogi/Takeda

Drug Profile

Lisdexamfetamine - Shionogi/Takeda

Alternative Names: Elvanse; Elvanse Adult; LDX; Lisdexamfetamine dimesilate; Lisdexamfetamine dimesylate; NRP-104; S-877489; SHP 489; SPD-489; Tyvense; Venvanse; Vyvanse

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New River Pharmaceuticals
  • Developer Lindner Center of HOPE; Shionogi; Shire; Takeda
  • Class Amides; Amphetamines; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Neuropsychotherapeutics; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder; Eating disorders
  • Phase II Mood disorders
  • Discontinued Bipolar depression; Cocaine abuse; Major depressive disorder; Schizophrenia; Sleep disorders

Most Recent Events

  • 10 Jul 2019 Registered for Attention-deficit hyperactivity disorder (In children) in Canada (PO, Tablet)
  • 26 Mar 2019 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top